Thursday - September 18, 2025
Cirius Therapeutics, Breakthrough T1D and UVA Health Collaborate on Phase 2 Study of MPC Inhibitor CIR-0602K in Type 1 Diabetes
September 17, 2025
NEW YORK, Sept. 17 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:

* * *

Cirius Therapeutics, Breakthrough T1D and UVA Health Collaborate on Phase 2 Study of MPC Inhibitor CIR-0602K in Type 1 Diabetes

*

* Breakthrough T1D awarded funding to University of Virginia for placebo-controlled clinical trial in people on automated insulin delivery

* Evalu . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products